Artemis Therapeutics, Inc. (ATMS) financial statements (2020 and earlier)

Company profile

Business Address 18 EAST 16TH STREET
NEW YORK, NY 10003
State of Incorp. DE
Fiscal Year End December 31
SIC 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments37525907658
Cash and cash equivalents37525907628
Short-term investments    30
Prepaid expense    48
Other undisclosed current assets17205865 
Total current assets:2027583972706
Noncurrent Assets
TOTAL ASSETS:2027583972706
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities156161535850
Accrued liabilities156161535850
Derivative instruments and hedges, liabilities 163   
Total current liabilities:156324535850
Noncurrent Liabilities
Liabilities, other than long-term debt100    
Due to related parties100    
Other undisclosed noncurrent liabilities  428 5
Total noncurrent liabilities:100 428 5
Total liabilities:2563244815855
Stockholders' equity
Stockholders' equity attributable to parent(236)(297)102914651
Common stock5252522,887432
Additional paid in capital1,9021,5711,457(1,709)17,796
Accumulated other comprehensive income    118
Accumulated deficit(2,190)(1,920)(1,407)(264)(17,695)
Total stockholders' equity:(236)(297)102914651
TOTAL LIABILITIES AND EQUITY:2027583972706

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(169)(772)(1,039) (164)
Operating loss:(169)(772)(1,039) (164)
Nonoperating income (expense)2259(104) 25
Investment income, nonoperating2259   
Foreign currency transaction loss, before tax    (7)
Other nonoperating expense  (104) (10)
Net loss attributable to parent:(167)(513)(1,143) (139)
Preferred stock dividends and other adjustments9(77)(171)  
Other undisclosed net income (loss) available to common stockholders, basic(572)154342  
Net loss available to common stockholders, diluted:(730)(436)(972) (139)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(167)(513)(1,143) (139)
Comprehensive loss, net of tax, attributable to parent:(167)(513)(1,143) (139)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: